EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Evolving First-Line Endocrine Therapy in HR+/HER2− Metastatic Breast Cancer: CDK4/6 Inhibition, Biomarker-Guided Strategies and Emerging Therapeutic Paradigms

Hikmat Abdel-Razeq iD, Baha Sharaf iD

Current Oncology · 14.07.2026 · 33 (7) · 421

DOI: 10.3390/curroncol33070421 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 14.07.2026. Verfasst von Hikmat Abdel-Razeq und 1 weiteren Autor:innen. Beteiligte Einrichtung: Section of Hematology and Medical Oncology, Department of Internal Medicine, King Hussein Cancer Center, Amman 11941, Jordan. Hauptthemen laut MEDLINE: Breast Neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Protein Kinase Inhibitors. Die Arbeit nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) metastatic breast cancer (MBC) is the most prevalent subtype of advanced breast cancer and is predominantly driven by estrogen receptor (ER) signaling. Endocrine therapy (ET) has become the backbone of first-line treatment; however, both intrinsic and acquired resistance limit long-term disease control. The introduction of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors has fundamentally reshaped the therapeutic landscape even in subsets of patients with aggressive or symptomatic visceral metastatic disease. Advances in molecular profiling have also enabled more precise, adaptive therapy. Circulating tumor DNA (ctDNA)-based liquid biopsy now allows real-time detection of emerging resistance mutations, particularly in ESR1. Additionally, patients with PIK3CA-mutated tumors who had progressed on or within 12 months of completing adjuvant ET and had no prior systemic therapy for metastatic disease had better treatment outcomes when treated with the PI3K inhibitor inavolisib in combination with palbociclib and fulvestrant. Together, these developments mark a shift from fixed treatment sequencing toward a more dynamic, biomarker-driven approach in first-line HR+/HER2– MBC. Integration of CDK4/6 inhibitors with next-generation endocrine agents and liquid biopsy-guided therapy offers the potential to delay resistance, improve survival outcomes, and individualize treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsAntineoplastic Agents, HormonalHumansFemaleBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesNeoplasm MetastasisReceptors, EstrogenReceptors, Progesterone

Stichwörter der Autor:innen

CDK4/6 inhibitorsESR1HR-positivectDNAendocrine therapymetastatic breast cancer

Substanzen

Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Biomarkers, TumorErb-b2 Receptor Tyrosine KinasesProtein Kinase InhibitorsCDK4 protein, humanReceptors, EstrogenCDK6 protein, humanERBB2 protein, humanAntineoplastic Agents, Hormonal

Autor:innen und Institutionen

  • Section of Hematology and Medical Oncology, Department of Internal Medicine, King Hussein Cancer Center, Amman 11941, Jordan.
  • School of Medicine, The University of Jordan, Amman 11942, Jordan.

ORCID-Profile: Hikmat Abdel-Razeq, Baha Sharaf

Zitieren

APA

Abdel-Razeq, H., & Sharaf, B. (2026). Evolving First-Line Endocrine Therapy in HR+/HER2− Metastatic Breast Cancer: CDK4/6 Inhibition, Biomarker-Guided Strategies and Emerging Therapeutic Paradigms. Current Oncology, 33(7), 421. https://doi.org/10.3390/curroncol33070421

Vancouver

Abdel-Razeq H, Sharaf B. Evolving First-Line Endocrine Therapy in HR+/HER2− Metastatic Breast Cancer: CDK4/6 Inhibition, Biomarker-Guided Strategies and Emerging Therapeutic Paradigms. Current Oncology. 2026;33(7):421. doi:10.3390/curroncol33070421

BibTeX
@article{AbdelRazeq2026,
  author = {Abdel-Razeq, Hikmat and Sharaf, Baha},
  title = {Evolving First-Line Endocrine Therapy in HR+/HER2− Metastatic Breast Cancer: CDK4/6 Inhibition, Biomarker-Guided Strategies and Emerging Therapeutic Paradigms},
  journal = {Current Oncology},
  year = {2026},
  volume = {33},
  number = {7},
  pages = {421},
  doi = {10.3390/curroncol33070421}
}
Kostenlos starten →